These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 38660003)

  • 1. Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates.
    Prajjwal P; Marsool MDM; Yadav V; Kanagala RSD; Reddy YB; John J; Lam JR; Karra N; Amiri B; Islam MU; Nithya V; Marsool ADM; Gadam S; Vora N; Hussin OA
    Health Sci Rep; 2024 Apr; 7(4):e2072. PubMed ID: 38660003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of complications associated with systemic sclerosis.
    Moore SC; Desantis ER
    Am J Health Syst Pharm; 2008 Feb; 65(4):315-21. PubMed ID: 18238768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.
    Abraham D; Lescoat A; Stratton R
    Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.
    Chong WH; Saha BK; Beegle S
    Am J Med Sci; 2023 Feb; 365(2):198-204. PubMed ID: 35276077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis.
    Lomeo RM; Cornella RJ; Schabel SI; Silver RM
    Am J Med; 1989 Nov; 87(5):525-7. PubMed ID: 2683765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
    Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario.
    Pătrîntașu DE; Sárközi HK; Lupușor E; Vlangăr IE; Rotariu GM; Rența IA; Nan AN; Budin CE
    Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
    Ferreli C; Gasparini G; Parodi A; Cozzani E; Rongioletti F; Atzori L
    Clin Rev Allergy Immunol; 2017 Dec; 53(3):306-336. PubMed ID: 28712039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
    Bellando-Randone S; Del Galdo F; Lepri G; Minier T; Huscher D; Furst DE; Allanore Y; Distler O; Czirják L; Bruni C; Guiducci S; Avouac J; Cutolo M; Smith V; Matucci-Cerinic M;
    Lancet Rheumatol; 2021 Dec; 3(12):e834-e843. PubMed ID: 38287630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
    Coelho Horimoto AM; da Costa IP
    Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics of children with scleroderma in a referral hospital].
    Morel Z; Benadón E; Faugier E; Maldonado Mdel R
    Reumatol Clin; 2009; 5(4):158-62. PubMed ID: 21794601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive Systemic Sclerosis With Negative Antinuclear Antibodies and Absence of Raynaud's Phenomenon: A Case Report and Literature Review.
    Falls AC; Wrigley C; Khanna SA
    Cureus; 2023 Mar; 15(3):e35663. PubMed ID: 37012951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Sclerosis Sine Scleroderma in Mexican Patients. Case Reports.
    Vera-Lastra O; Sauceda-Casas CA; Domínguez MDPC; Alvarez SAM; Sepulceda-Delgado J
    Reumatol Clin (Engl Ed); 2018; 14(4):230-232. PubMed ID: 28065485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scleroderma lung: pathogenesis, evaluation and current therapy.
    van Laar JM; Stolk J; Tyndall A
    Drugs; 2007; 67(7):985-96. PubMed ID: 17488144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical Scleroderma-like Chronic GVHD in a Liver Transplant Patient, Clinical and MRI Correlations.
    Giannoni M; Rizzetto G; Diotallevi F; Molinelli E; Radi G; Campanati A; Brancorsni D; Offidani A
    Acta Dermatovenerol Croat; 2022 Sep; 30(2):123-125. PubMed ID: 36254548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic sclerosis].
    Legendre P; Mouthon L
    Rev Prat; 2017 Sep; 67(7):775-783. PubMed ID: 30512777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.
    Strange G; Nash P
    Int J Rheum Dis; 2009 Sep; 12(3):192-206. PubMed ID: 20374346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and sociodemographic features of Puerto Ricans with systemic sclerosis.
    Ríos G; Mayor AM
    Ethn Dis; 2010; 20(1 Suppl 1):S1-185-9. PubMed ID: 20521412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.